No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BLFS240517C15000
- 2.25
- 0.000.00%
15min DelayTrading Apr 23 09:45 ET
0.00High0.00Low
0.00Open2.25Pre Close0 Volume3 Open Interest15.00Strike Price0.00Turnover364.64%IV3.81%PremiumMay 17, 2024Expiry Date5.76Intrinsic Value100Multiplier4DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.8469Delta0.0284Gamma3.17Leverage Ratio-0.2301Theta0.0013Rho2.68Eff Leverage0.0054Vega
Intraday
- 5D
- 1D
News
Express News | BioLife Solutions Shares Are Trading Higher After Benchmark Ugpraded the Stock From Hold to Buy and Announced a $25 Price Target
Correction to BioLife Solutions Ratings
"BioLife Solutions Raised to Buy From Neutral by Benchmark" at 7:31 a.m. ET incorrectly stated that BioLife Solutions was raised to buy from Neutral. It was raised to buy from hold.
Express News | BioLife Solutions Inc : Craig-Hallum Raises Target Price to $23 From $21
BioLife Solns Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 30.21% Benchmark → $25 Upgrades Neutral → Buy 04/04/2024 14.58% Jefferies → $22 Initiates Cover
Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target
BioLife Solutions (BLFS) has an average buy rating and a price target range of $20 to $30, according to analysts polled by Capital IQ.
Express News | BioLife Solutions Inc : Benchmark Raises to Buy
Comments
BioLife Solutions, despite more cash than debt, is seen as risky due to lack of profitability and negative cash flow. The company's future financial health hinges on its earnings.
Is BioLife Solutions (NASDAQ:BLFS) Using Too Much Debt? 1
The stock's low price indicates a potential buying opportunity. However, its high beta suggests volatility. The company's optimistic future outlook isn't fully reflected in the current share price.
BioLife Solutions' worrying forecast of increased losses and reduced revenues could wane investor confidence. The company's long-term business trajectory is vital for creating shareholder value.
Lack of insider transactions might be discouraging for the company's share outlook and the stated insider ownership is not really impressive.
Core points:
1. There are three platforms: first, cell processing, which includes biopreservation media and Sexton cell processing products; second is our freezers and thaw systems platform comprised of cryogenic liquid nitrogen freezers and Sterling ULT mechanical freezers and automated thawing Instruments; and finally, storage and storage services, which includes our SciSafe storage services and our evo col...
1. There are three platforms: first, cell processing, which includes biopreservation media and Sexton cell processing products; second is our freezers and thaw systems platform comprised of cryogenic liquid nitrogen freezers and Sterling ULT mechanical freezers and automated thawing Instruments; and finally, storage and storage services, which includes our SciSafe storage services and our evo col...
Read more